RXRX
Recursion Pharmaceuticals, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$4.03Close
$2.1BMarket cap
$2.84 – $5.6552-week range
Nov 4, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 29% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
29%
1wk
up 8.9%
price change
1mo
down 2.4%
price change
12-month return
down 29%
market up 11% ·
its own down 42%
F-score
4 / 9
Weak
Altman Z
0.89
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.9×
price / book
Earnings yield
down 46.5%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
up 27%
year on year
EPS growth
—
latest quarter
Sales growth
down 60%
latest quarter · -4 pts
ROE
down 60%
return on equity
Free cash margin
down 507%
-$378.3M FCF
D/E
0.01
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
Repair signals
- Long-term debt down 50% ($0.0B → $0.0B)
Trade setup
ATR%
8.9%
$0.36 a day · 2×ATR $3.31
RS
58 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.32
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 33.1% over the year, from 397m to 528m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 23.1% to 5.0%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 15, 2026
Results reaction
Oct 15, 2026-7% vs market2 sessions after results
Financials
- Gross 5%
- Net -863%
- Free cash -507%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0M | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Gross margin | 100% | 100% | -21% | 4% | 23% | 5% |
| Operating income | -$84.6M | -$182.8M | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| Net income | -$87.0M | -$186.5M | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| Net margin | -2196% | -1832% | -601% | -736% | -788% | -863% |
| Earnings per share | -$3.99 | -$1.49 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Free cash flow | -$51.2M | -$198.4M | -$120.6M | -$299.7M | -$372.9M | -$378.3M |
| Free cash margin | -1293% | -1949% | -303% | -672% | -634% | -507% |
| Cash | $262.1M | $285.1M | $549.9M | $391.6M | $594.4M | $743.3M |
| Long-term debt | $11.4M | $723,000 | $536,000 | $1.1M | $19.0M | $9.6M |
| Shareholders' equity | -$206.3M | $542.9M | $485.8M | $463.4M | $1.0B | $1.1B |
| Shares outstanding | 22.31m | 170.27m | 191.02m | 234.27m | 396.80m | 528.18m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 15, 2026 | Material agreement · Results · Regulation FD · Other events ↗ |
| Sep 21, 2026 | Material agreement ↗ |
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| Apr 30, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 25, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 25, 2026 | Results · Regulation FD ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Dec 8, 2025 | Other events ↗ |
| Nov 26, 2025 | Other events ↗ |
| Nov 5, 2025 | Results · Director or officer change · Regulation FD ↗ |